Altimmune Q2 EPS $(0.32) Beats $(0.46) Estimate, Sales $6.00K Down From $8.00K YoY
Portfolio Pulse from Benzinga Newsdesk
Altimmune (NASDAQ:ALT) reported Q2 losses of $(0.32) per share, beating the analyst consensus estimate of $(0.46) by 30.43%. This is a 23.81% increase over losses from the same period last year. However, the company's sales decreased by 25.00% to $6.00K from $8.00K YoY.
August 10, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Altimmune's Q2 earnings beat analyst estimates, but sales decreased YoY.
Altimmune's Q2 earnings beat analyst estimates, which is positive for the stock. However, the decrease in sales YoY could offset this positive impact, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100